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Contents l ists avai lable at ScienceDirectEditorialIs Klotho deﬁciency independently associated with cardiovascular
risk in chronic kidney disease?Patients with chronic kidney disease (CKD) suffer from a
high burden of cardiovascular disease (CVD) [1]. This is partly
due to progressive deterioration of calciumephosphate ho-
meostasis. Although the molecular mechanism of action of
Klotho is not well understood, ﬁbroblast growth factor-23
(FGF-23) and its coreceptor Klotho have emerged as pivotal
players in calciumephosphate homeostasis. Klotho was ﬁrst
identiﬁed in mice, where mutations of the gene led to a syn-
drome resembling premature aging [2]. The Klotho protein ex-
ists in both a membrane bound and a soluble form (sKlotho).
sKlotho is derived from the extracellular part of membranous
Klotho through alternative splicing of the Klotho gene and
has a unique role in renal calcium and phosphate excretion in-
dependent of FGF-23 [3]. There is growing interest in using
sKlotho as an important biomarker of kidney function, based
largely on studies showing that blood and urine concentrations
of sKlotho decrease early in the course of CKD [4,5].
In addition, sKlotho has also been explored for a potential
biomarker for CVD. In this issue, Abdallah et al [6] investigated
the association between sKlotho and CVD risk in hemodialysis
patients. They measured sKlotho and FGF-23 in 88 regular
hemodialysis patients and 28 normal populations (control
group), using a commercially available enzyme-linked immuno-
sorbent assay. For evaluationof CVD, carotid intimal-media thick-
ness and left ventricular (LV) dysfunction were estimated by
ultrasonography. The sKlotho level was signiﬁcantly low in
hemodialysis patients compared to controls, and FGF-23 was
signiﬁcantly high in hemodialysis patients compared to controls.
The concentrations of parathyroid hormone, FGF-23, and
phosphate were signiﬁcantly higher when the Klotho level was
lower (< 476 pg/mL, n¼ 44). In contrast, serum calcium was
signiﬁcantly lower when the sKlotho level was lower. Notably,
the prevalence of coronaryartery disease (CAD)washigher inpa-
tients with a lower sKlotho level. Regression analysis of sKlotho
for the relationship with different markers of CVD revealed that
sKlotho was signiﬁcantly associated with carotid intimal-media
thickness, LV ejection fraction, and CAD. However, these data
have some limitations. Data on dietary phosphate intake, a
knowndeterminant for both serumphosphate andFGF-23 levels,
were not collected. Because sKlotho has a circadian variation,
measurement at ﬁxed time is necessary [7]. Similarly, a reduced
Klotho level was associated with the presence and severity ofhttp://dx.doi.org/10.1016/j.krcp.2016.01.001
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).CAD [8]. On the other hand, sKlothowas not independently asso-
ciated with CVD in a population of dialysis patients [9]. Buiten
etal [9]evaluated theassociationbetweensKlothoandcardiovas-
cular outcomes in dialysis patients, showing that patients with a
lower sKlotho (< 460pg/mL)were associatedwithmoreCADand
LVdysfunction.Afteradjusting forconfounders,however, sKlotho
was not independently associated with the presence of CVD.
Despite mixed results of sKlotho level and CVD risk from
clinical studies, most animal study results support that Klotho
deﬁciency is associated with CVD risk. Klotho deﬁciency in
mice resulted in hyperphosphatemia, hypervitaminosis D,
hypercalcemia, arteriosclerosis, and ectopic calciﬁcation
including vascular calciﬁcation [2,4]. Transgenic CKD mice
overexpressing Klotho had better kidney function, enhanced
phosphaturia, and less soft tissue calciﬁcation as compared
with wild-type mice with CKD [4]. Interaction of Klotho with
FGF-23 receptor leads to phosphaturia because of the inhibition
of sodium-dependent phosphate cotransporter type IIa in the
brush-border membrane of proximal renal tubular cells. Inde-
pendent from FGF-23, soluble urinary Klotho has been found
to directly regulate the phosphate transport. In the proximal tu-
bule of the kidney, it promotes internalization of sodium-
dependent phosphate cotransporter type IIa by deglycosylation
[4]. These effects of Klotho on urinary phosphate excretion
probably contribute to its inhibitory effects on calciﬁcation.
In brief, recent studies suggest that sKlotho deﬁciency
should be a good explanation for the high risk of CVD in CKD.
However, further studies are required to demonstrate whether
sKlotho is just a biomarker or a predictor of CVD in CKD and
dialysis patients.
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